Who are OBINUTUZUMAB's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ocrevus, Gazyva, RITUXIMAB, Mabthera, Mabthera, RIABNI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl1743048.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

OBINUTUZUMAB — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

OBINUTUZUMAB (OBINUTUZUMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD20-directed Cytolytic Antibody [EPC].

marketed CD20-directed Cytolytic Antibody [EPC] Monoclonal antibody Live · refreshed every 30 min

Target snapshot

OBINUTUZUMAB (OBINUTUZUMAB).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
OBINUTUZUMAB TARGET	OBINUTUZUMAB		marketed	CD20-directed Cytolytic Antibody [EPC]		2013-01-01
Ocrevus	OCRELIZUMAB	Roche	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	2017-01-01
Gazyva	obinutuzumab	Roche	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	2013-01-01
RITUXIMAB	RITUXIMAB		marketed	CD20-directed Cytolytic Antibody [EPC]		1997-01-01
Mabthera	rituxan	Roche	marketed	CD20-directed Cytolytic Antibody	B-lymphocyte antigen CD20	1997-01-01
Mabthera	rituximab	Roche	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	1997-01-01
RIABNI	RITUXIMAB-ARRX	AMGEN INC	marketed	CD20-directed Cytolytic Antibody [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD20-directed Cytolytic Antibody [EPC] class)

Roche · 3 drugs in this class
· 2 drugs in this class
AMGEN INC · 1 drug in this class
CELLTRION INC · 1 drug in this class
TG THERAPEUTICS, INC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OBINUTUZUMAB — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl1743048. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab